These findings could explain the reduction in Aβ levels and plaque burden observed in AD mouse models chronically treated with CB2 or CB1/CB2 receptor agonists (Martín-Moreno et al., 2012) and MAGL inhibitors (Chen et al., 2012; Piro et al., 2012). Here, CNR1 is linked to Alzheimer disease.